At 8:47 a.m. on May 5, with The Successful Completion of the Yttrium-90 Resin Microsphere Injection by Professor Teng Gaojun, Academician of the Chinese Academy of Sciences, President of the Zhongda Hospital Affiliated to Southeast University, and Director of the Interventional Diagnosis and Treatment Center, it marked the success of the first case of yttrium-90 resin microsphere injection jointly carried out by Academician Teng Gaojun led by Zhu Haidong, Zhang Qi, and Liu Jiacheng, deputy director of the Department of Nuclear Medicine, and other team members.
△ Academician Teng Gaojun (first from the right) led the team to operate on the patient. Photo by Wang Qian
Zhu Haidong, deputy chief physician of the Interventional Diagnosis and Treatment Center of CUHK, said that the number of new cases of colorectal cancer is about 380,000 every year, of which half have liver metastases, and the survival time without treatment is only 6.9 months. The commonly used treatment methods for secondary liver malignancies include surgical resection, local ablation, selective internal radiation therapy, external radiation therapy, chemotherapy, molecular targeted therapy, etc., but they are often affected by various factors such as tumor location, number of lesions, blood supply characteristics of lesions, liver function reserves, etc., resulting in some treatments that cannot be implemented or have poor results.
Zhang Qi, deputy chief physician of the Interventional Diagnosis and Treatment Center of CUHK, told reporters that the patient is 51 years old and has been clearly diagnosed as colorectal cancer liver metastasis after careful examination. The interventional surgery was strictly in accordance with the standardized process, and after several rounds of discussions by overseas supervision experts and domestic multidisciplinary consultation experts, it was finally unanimously determined that patients were the best choice for yttrium-90 resin microsphere therapy. It is reported that the yttrium 90 resin microspheres are like a "super nuclear bomb" that can be accurately delivered to overcome tumors, through precise positioning, the yttrium 90 resin microspheres are injected into the liver blood vessels, releasing high-energy β radiation, which can kill tumor cells instantaneously at close range, have almost no impact on normal liver tissue and the surrounding environment, and can also be combined with other comprehensive treatment methods such as biology, immunity, and targeting, bringing more significant clinical benefits to the majority of patients with liver malignant tumors.
According to reports, yttrium-90 resin microspheres are the first therapeutic radiopharmaceutical approved by the State Food and Drug Administration in 2022, and the first product in China to be approved for the treatment of liver metastases of colorectal cancer. As the first radioactive microsphere product officially approved for colorectal liver transfer approved by the US Food and Drug Administration, yttrium 90 resin microsphere injection has been treated more than 120,000 times in more than 50 countries and regions around the world, without obvious adverse reactions, and its safety and efficacy have been fully verified, and recommended by mainstream diagnosis and treatment guidelines in the United States and Europe.
Academician Teng Gaojun pointed out that this operation is the first patient with colorectal cancer liver metastasis to benefit after the yttrium 90 resin microsphere injection was approved for marketing in China, and the successful implementation of the operation has brought new hope to patients with colorectal cancer liver metastasis. At present, a large number of data show that yttrium 90 resin microsphere injection provides a good opportunity for the downphase of liver malignancies and for subsequent surgical conversion treatment. As the cradle of domestic interventional physician training, the interventional diagnosis and treatment center of cuntical hospital affiliated to Southeast University is innovation, the team continues to innovate and explore in the field of interventional diagnosis and treatment, and will introduce more international advanced medical technology into the hospital in the future to benefit the majority of patients with liver malignant tumors.
Correspondent Cheng Shouqin Liu Min Wang Qian Modern Express + reporter Liu Jun